Tirzepatide vs Semaglutide: Which One Is Actually Better for You?

For the first time in history, we have two extraordinarily effective medications for weight loss — and patients are reasonably asking: which one is better?

The honest answer is that tirzepatide wins on the clinical data, but the right choice depends on you. Let's look at both the head-to-head evidence and the factors that matter for individual decisions.

The Mechanism Difference

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist. It works by mimicking the GLP-1 hormone your gut releases after eating — signaling your brain that you're full, slowing gastric emptying, improving insulin sensitivity.

Tirzepatide (Mounjaro/Zepbound) does all of that — plus it also activates GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone with distinct effects: it acts on adipose tissue to reduce fat storage, has independent effects on insulin secretion from pancreatic beta cells, and may have additional central effects on appetite regulation.

The dual mechanism is why tirzepatide is more potent on average. Two receptor activations produce greater metabolic effects than one.

The Clinical Evidence: Head-to-Head

For years, we could only compare the trials indirectly — STEP 1 (semaglutide) versus SURMOUNT-1 (tirzepatide) were different studies with different populations and methodologies.

The SURMOUNT-5 trial settled this with a direct head-to-head comparison: tirzepatide versus semaglutide, same populations, same trial design. The results:

Tirzepatide: 20.2% average total body weight loss over 72 weeks Semaglutide: 13.7% average total body weight loss over 72 weeks

Tirzepatide produced 47% more weight loss than semaglutide in a controlled head-to-head trial. This is not a marginal difference.

Earlier trials also support tirzepatide's edge: - SURMOUNT-1: 22.5% average weight loss at highest dose (tirzepatide 15mg) - STEP 1: 14.9% average weight loss at highest dose (semaglutide 2.4mg)

Where Semaglutide Still Wins

Despite tirzepatide's superior weight loss data, semaglutide has meaningful advantages in specific contexts:

Cardiovascular outcomes evidence: The SELECT trial (2023) demonstrated that semaglutide reduces major cardiovascular events by 20% in patients with cardiovascular disease and overweight/obesity — even without significant weight loss. This was landmark data. Tirzepatide has the SURPASS-CVOT trial (results expected 2026), but the cardiovascular outcomes data for semaglutide is more established.

More GLP-1 experience: Semaglutide (as Ozempic) has been in widespread use since 2017. There is simply more long-term real-world data on it. Tirzepatide was only approved in 2022.

Some physicians prefer for GI-sensitive patients: There's clinical observation (though not robust trial data) suggesting tirzepatide's GIP component may slightly reduce GI side effects for some patients. But this isn't universal, and for patients with severe GI sensitivity, semaglutide may be preferred as the better-studied option.

Escalation path: For patients who've plateaued on semaglutide, tirzepatide represents a natural step up. Having semaglutide as a starting point preserves optionality.

Side Effect Comparison

Both medications share the same core side effect profile: - Nausea (most common, especially early) - Constipation - Diarrhea - Fatigue during titration - Decreased appetite (this is the mechanism, not technically a side effect)

The severity of side effects is similar across trials. Some studies suggest tirzepatide may have slightly lower nausea rates than semaglutide — possibly because GIP receptor activation counteracts some GI effects of GLP-1 activation. But this is a modest difference, and individual responses vary enormously.

The most important factor for tolerability: slow titration. Both medications should be started at the lowest dose and increased gradually. Rushing the titration is the primary cause of treatment discontinuation due to side effects.

Cost Comparison at Marrow

At Marrow, compounded semaglutide starts at $249/month and compounded tirzepatide starts at $299/month. The $50 difference reflects tirzepatide's higher manufacturing cost.

Given the superior average weight loss outcomes, tirzepatide often delivers better value per pound lost — but cost is a real factor for patients on fixed budgets.

How to Choose

Choose tirzepatide if: - Maximum weight loss is the primary goal - You've previously tried semaglutide and plateaued - You can afford the slight cost premium - You don't have established cardiovascular disease (where semaglutide's SELECT data may be relevant)

Choose semaglutide if: - You have established cardiovascular disease (cardiovascular outcomes data is stronger) - Budget is a significant concern - Your physician prefers the more established data profile - You've had GI issues with other medications and want the more-studied option

Ask your physician if: - You have Type 2 diabetes (different dosing considerations) - You have any history of thyroid cancer or MEN2 - You're on other medications that interact with GLP-1 agonists

The right answer depends on your body, your history, and your goals. [Start your intake at Marrow](/start) and our physician will help you choose the protocol that fits.